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Introduction {#sec005}
============

The tegumentary form of the leishmaniasis can be classified in two main clinical forms: cutaneous and mucosal. Mucosal leishmaniasis (ML) is primarily caused by *Leishmania braziliensis* (*L*. *braziliensis*), and it occurs months or years after the cutaneous lesions have healed \[[@pone.0218786.ref001]\]. Mucosal leishmaniasis is a progressive disease that can destroy cartilages and the osseous structures of the face, pharynx, and larynx \[[@pone.0218786.ref002]\]. Most ML cases are treated with antimonial pentavalent. However, this drug has several adverse effects (AEs) and contraindications \[[@pone.0218786.ref003]\]. Liposomal amphotericin B (L-AMB) is a safe option. However, the cost of this drug can be a limitation in developing countries, and the ideal dose is not established.

L-AMB is the first-line treatment for visceral leishmaniasis \[[@pone.0218786.ref004]\], and it has been used for mucocutaneous leishmaniasis with controversial results. In some studies, the healing rate was similar to those who were not on therapy \[[@pone.0218786.ref005]\]. The variability of clinical response to L-AMB is associated with the *Leishmania* species. In Brazil, studies have found different cure rates \[[@pone.0218786.ref006], [@pone.0218786.ref007]\].

Considering the controversial benefits of L-AMB on the treatment of ML, the present study aimed to evaluate the treatment outcome of the largest cohort of patients with ML who were treated with liposomal amphotericin in comparison with other treatments.

Methods {#sec006}
=======

This is a retrospective study that included a cohort of patients with a confirmed diagnosis of ML who received at least one treatment with any leishmanicidal drugs from January 2000 to July 2015. The study was approved by the local ethical committee (CAPpesq number: 0576/11). Informed consent was waived by the ethics committee considering the characteristics of this study. All data were fully anonymized before access. Patients from the different cities of Brazil were treated in a reference hospital in Sao Paulo, SP, Brazil.

The inclusion criteria were as follows: patients with confirmed ML who were older than 18 years and followed-up for at least 6 months. Exclusion criteria included patients without confirmation of ML and refuse to treatment. The diagnosis of ML consisted with the identification of *Leishmania* spp. in the tissue via molecular tests, culture, or the observation of the typical structure during histological examination or immunohistochemistry \[[@pone.0218786.ref008]\]. Otorhinolaryngological examinations were performed by the same physician throughout the study period.

The clinical variables included in the analysis were gender, age, Brazilian state of origin, race, previous cutaneous lesions suggesting cutaneous leishmaniasis, comorbidities, duration of the symptoms, site of the ML, symptoms, serum and cutaneous tests, and tomographic and clinical findings, as previously classified \[[@pone.0218786.ref009], [@pone.0218786.ref010]\].

The therapeutic options for the treatment of ML consisted of L-AMB (1--4 mg/kg/day), amphotericin B lipid complex (ABLC) (1--4 mg/kg/day), deoxycholate amphotericin B (d-AMB) (1 mg/kg/day), itraconazole (200 mg/day for 6 weeks), antimonial pentavalent (20 mg/Sb^+5^/kg/day for 30 days), or pentamidine (4 mg/kg for 10 days). All formulations of amphotericin B should achieve a cumulative dose of 2,500 mg. Antimonial pentavalent was considered the drug of first choice. In the case of contraindications, the second choice drugs used were pentamidine and amphotericin B. For those cases where these therapeutic options were used without success or presented contraindication, lipid formulations of amphotericin B has been used. For refractory cases or contraindication to all therapeutic regimens, itraconazole was used.

Cure was defined as the total healing of mucosal lesion based on otorhinolaryngological and fiberoptic examinations until 1 year after the end of the therapy. Failure is defined as the absence of lesion improvement after therapy or the return of lesions before 1 year. Lesions that showed an improvement after 6 months of therapy but did not completely heal were considered failure. Recurrence is considered as new lesions or the return of the lesion after 1 year of therapy \[[@pone.0218786.ref011]\].

In addition, the AEs associated with the treatment of ML were analyzed during the hospitalization period: fever, headache, nausea or vomiting, tremors or chills, sweating, phlebitis on the infusion site, low back pain, chest pain, palpitation, myalgia, arthralgia, asthenia, and rashes. Systemic AEs included acute kidney injury (AKI) according to the AKIN criteria \[[@pone.0218786.ref012]\], electrolyte imbalance, hepatic enzyme alterations, pancreatic enzyme alterations, myelotoxicity, electrocardiographic changes, and hypoglycemia. Changes in hepatic and pancreatic enzymes were considered when their values exceeded three times the baseline value or, in the absence of baseline values, when they exceeded three times the normal limit. Myelotoxicity was considered when hemoglobin level decreases by 2 points from baseline, total leukocyte level is below 3,000/mm^3^, and/or platelet count is below 150,000/mm^3^.

Data of the patients were organized as general data, and the risk factors of the treatment were evaluated. New cases included patients who received more than one treatment during follow-up. Thus, in 71 patients, a total of 105 treatments were analyzed. The number of treatments exceeded the number of patients because one patient could be followed more than one treatment. A successful treatment was considered when achieved complete healing within 3 months. The secondary treatment followed a protocol using the different chemotherapy schedule.

Continuous data were expressed as mean or median with standard deviation (SD) or ranges. Frequencies were expressed as percentages. Categorical, continuous, and dichotomized independent variables were analyzed with forward conditional factorial binary logistic regression model to determine the statistical significance of the clinical and epidemiological findings, diagnosis, and treatment along with the outcome and recurrence of ML. A P-value \<0.05 was considered statistically significant. All data were recorded in Microsoft Excel (Microsoft), and statistical analysis was performed using SPSS version 23.

Results {#sec007}
=======

In 71 patients, a total of 105 treatments were evaluated. All patients have a confirmed diagnosis of ML. The mean age of the patients was 59.9 years, and approximately 61% of the study participants were men. Most patients came to our service with symptoms for more than 5 years (65.4%). The most common symptoms were epistaxis, nasal obstruction, and rhinorrhea. The nasal mucosa was the more commonly affected site in leishmaniasis (75.2%), followed by the pharynx and palate ([Table 1](#pone.0218786.t001){ref-type="table"}). Additional data are available in the [S1 File](#pone.0218786.s001){ref-type="supplementary-material"}.

10.1371/journal.pone.0218786.t001

###### Clinical and laboratorial findings of 71 patients with mucosal leishmaniasis.
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  Data                                 N = 71                                    \%                                                                                               
  ------------------------------------ ----------------------------------------- -------------------------------------------- ------ -------------------------------------------- ------
  Brazilian Region                                                                                                                                                                
                                       Northeast                                 36                                           50.7                                                 
                                       Southeast                                 21                                           29.6                                                 
                                       South                                     6                                            8.4                                                  
                                       North                                     2                                            2.9                                                  
                                       Midwest                                   6                                            8.4                                                  
  Sex                                                                                                                                                                             
                                       Female                                    27                                           38.0                                                 
                                       Male                                      44                                           62.0                                                 
  Age (years±SD)                       59.1±14.2                                                                                                                                  
  Comorbidities                                                                                                                                                                   
                                       Systemic arterial hypertension            44                                           62.0                                                 
                                       Diabetes mellitus                         7                                            9.9                                                  
  Previous cutaneous lesions           37                                        52.1                                                                                             
                                       Inferior Limbs                            22                                           31.0                                                 
  Duration of symptoms                                                                                                                                                            
                                       \<1 year                                  12                                           17.0                                                 
                                       1--5 years                                16                                           22.5                                                 
                                       5--10 years                               30                                           42.2                                                 
                                       \>10years                                 13                                           18.3                                                 
  Symptoms                                                                                                                                                                        
                                       Epistaxis                                 48                                           68.5                                                 
                                       Nasal obstruction                         50                                           71.4                                                 
                                       Rhinorrhea                                38                                           54.2                                                 
                                       Nasal crust                               26                                           36.6                                                 
                                       Pruritus                                  16                                           22.5                                                 
                                       Cacosmia                                  14                                           19.7                                                 
                                       Sneeze                                    4                                            5.6                                                  
                                       Odynophagia                               9                                            12.7                                                 
                                       Hyposmia                                  6                                            8.5                                                  
                                       Facial pain                               10                                           14.1                                                 
  Local of the mucosal leishmaniasis                                                                                                                                              
                                       Nasal                                     55                                           78.5                                                 
                                       Palate                                    14                                           19.7                                                 
                                       Pharynx                                   18                                           25.4                                                 
                                       Larynx                                    10                                           14.2                                                 
  Nasofibroscopy                                                                                                                                                                  
                                       Septal perfuration                        47                                           66.2                                                 
                                       Granulomatous activity                    38                                           54.3                                                 
                                       Crusts                                    45                                           64.2                                                 
                                       Edema                                     12                                           17.1                                                 
                                       Stenosis                                  14                                           20.0                                                 
                                       Bleeding                                  4                                            5.7                                                  
                                       Mucosal atrophy                           5                                            7.1                                                  
                                       Hyperemia                                 13                                           18.6                                                 
                                       Ulceration                                4                                            5.7                                                  
                                       Purulent drainage                         2                                            2.8                                                  
  Diagnosis                                                                                                                                                                       
                                       Histological exam                         70                                           98.5                                                 
                                       Positive immunohistochemistry             20                                           28.5                                                 
                                       Polymerase chain reaction (14 patients)   10                                           71.4                                                 
  Serum test                                                                                                                                                                      
                                                                                 ELISA[\*](#t001fn001){ref-type="table-fn"}          IIF[\*\*](#t001fn002){ref-type="table-fn"}    
                                       1:40                                      16                                           27.5   12                                           16.9
                                       1:80                                      5                                            7.0    7                                            9.8
                                       1:160                                     3                                            4.2    2                                            2.8
                                       1:320                                     9                                            12.6   0                                            0.0
                                       \>1:320                                   7                                            9.8    2                                            2.8
                                       Reagent without titre                     4                                            5.6    3                                            4.2
                                       Non reagent                               5                                            7.0    18                                           25.3
                                       Positive Montenegro test                  41                                           57.7                                                 
  CT scan findings (n = 48)                                                                                                                                                       
                                       Thickening of mucosa                      18                                           37.5                                                 
                                       Sinusopathy                               10                                           20.8                                                 
                                       Mastoideopathy                            4                                            14.3                                                 
  Hospitalization for treatment        57                                        80.3                                                                                             
                                       Duration of admission (days±SD)           22.7±10.5                                                                                        
                                       Treatment interrupted by side effect      31                                           43.6                                                 
  Follow up duration (months±SD)       55.6±46.6                                                                                                                                  
  Outcome                                                                                                                                                                         
                                       Cure                                      37                                           51.1                                                 
                                       Relapse                                   12                                           16.9                                                 
                                       Interruption by side effect               31                                           43.6                                                 
  Final cure                           46                                        64.8                                                                                             

\* ELISA (enzyme linked immunosorbent assay)

\*\*IIF---indirect immunofluorescence

Most patients reported a previous cutaneous lesion (52.4%), which was located mainly in the lower limbs. Moreover, 9 patients reported previous lesions in the upper limbs. One patient reported a lesion in the back, and another patient had a lesion in the penis. In addition, one patient reported a lesion in the face.

All patients were subjected to nasofibroscopy. Septal perforation was identified in 66.2% of the participants, followed by crusts and granulomatous inflammation of the mucosa. Computed tomography (CT) scan of the face has been included in the routine examination of ML since 2009. In 48 patients who were evaluated, 70.8% presented with mucosal thickening. Other findings are detailed in the [Table 1](#pone.0218786.t001){ref-type="table"}.

The treatment of all patients with ML was performed in the hospital with a mean hospitalization time of 22.9 days. In the treatment of these patients, L-AMB was the most commonly used drug (32), followed by pentavalent antimonial (25), d-AMB (14), ABLC (13), pentamidine (11), and itraconazole (10). The treatment outcome of each drug was compared, and results showed that L-AMB was superior than other therapeutic regimens (P = 0.001; odds ratio \[OR\] = 4.84; 95% confidence interval \[CI\]: 1.78--13.17). The risk factor associated with the healing was the absence of mucosal thickening on CT scan ([Table 2](#pone.0218786.t002){ref-type="table"}). From 105 treatments, healing was achieved in 61, but cure rate was only 64.8%. In the multivariable analysis, L-AMB was an independent variable associated with healing (P = 0.008), and absence of mucosal thickness on CT scan too (P = 0.038). The group of patients that received L-AMB was clinically similar with other treatments, except by stenosis in nasopharinx on nasofibroscopy exam ([Table 3](#pone.0218786.t003){ref-type="table"}).

10.1371/journal.pone.0218786.t002

###### Comparative data of patients with mucosal leishmaniasis with complete healing after treatment and without healing.
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                                                                                      Healing     No Healing                          
  -------------------------------------------------- -------------------------------- ----------- ------------ ------ ------- ------- ----------------------
  Sex                                                                                                                                 
                                                     Female                           23          37.7         18     40.9    0.448    
                                                     Male                             38          62.3         26     59.1             
  Age (years±SD)                                     60.2±14.3                        60.0±12.3   0.935                               
  Comorbidities                                                                                                                       
                                                     Systemic arterial hypertension   38          62.3         26     59.1    0.448    
                                                     Diabetes mellitus                5           8.2          6      13.6    0.534    
  Previous cutaneous lesions                         34                               55.7        21           47.7   0.611           
  Duration of symptoms                                                                                                                
                                                     \<1 year                         7           15.9         5      13.5    0.835    
                                                     1--5 years                       9           20.5         7      18.9             
                                                     5--10 years                      16          36.4         14     37.8             
                                                     \>10years                        12          27.3         11     29.7             
  Symptoms                                                                                                                            
                                                     Epistaxis                        41          65.6         33     75.0    0.283    
                                                     Nasal obstruction                44          70.5         31     70.5    0.478    
                                                     Rhinorrhea                       33          54.1         21     47.7    0.266    
                                                     Nasal crust                      23          37.7         23     52.3    0.127    
                                                     Pruritus                         16          26.2         10     22.7    0.393    
                                                     Cacosmia                         12          19.7         9      20.5    0.589    
                                                     Sneeze                           6           9.8          3      6.8     0.410    
                                                     Odynophagia                      6           9.8          8      18.2    0.188    
                                                     Hyposmia                         6           9.8          7      15.9    0.283    
                                                     Facial pain                      8           11.5         5      11.4    0.596    
  Local of the mucosal leishmaniasis                                                                                                  
                                                     Nasal                            46          75.4         33     75.0    0.569   
                                                     Palate                           9           14.8         13     29.5    0.061    
                                                     Pharynx                          14          23.0         16     36.4    0.110    
                                                     Larynx                           7           11.5         5      11.4    0.608    
  Nasofibroscopy                                                                                                                      
                                                     Septal perfuration               39          63.9         32     72.7    0.248    
                                                     Granulomatous activity           31          50.8         20     45.5    0.344    
                                                     Crusts                           39          63.9         26     59.1    0.353    
                                                     Edema                            8           13.1         8      18.2    0.336    
                                                     Stenosis                         10          16.4         11     25.0    0.372    
                                                     Bleeding                         2           3.3          2      4.5     0.564    
                                                     Mucosal atrophy                  3           4.9          6      13.6    0.115    
                                                     Hyperemia                        9           14.8         11     25.0    0.158    
                                                     Ulceration                       2           3.3          5      11.4    0.110    
                                                     Purulent drainage                1           1.6          2      4.5     0.382    
  CT scan findings (n = 48)                                                                                                           
                                                     Thickening of mucosa             16          26.2         18     40.9    0.044   0.24 \[0.05--1.02\]
                                                     Sinusopathy                      8           13.1         5      11.4    0.454    
                                                     Mastoideopathy                   2           3.3          3      6.8     0.379    
  Therapy[\*\*\*](#t002fn001){ref-type="table-fn"}                                                                                    
                                                     L-AMB                            26          81.3         6      18.7    0.001   4.84 \[1.78--13.17\]
                                                     d-AMB                            2           13.3         12     86.7    0.001   0.09 \[0.01--0.43\]
                                                     ABLC                             6           46.1         7      53.9    0.272   0.58 \[0.18--1.88\]
                                                     Antimonial pentavalent           14          56.0         11     44.0    0.567   1.03 \[0.41--2.60\]
                                                     Itraconazole                     4           40.0         6      60.0    0.196   0.45 \[0.12--1.71\]
                                                     Pentamidine                      8           72.7         3      27.3    0.231   2.10 \[0.52--8.43\]

\*\*\* Percentages for therapy are related with patients treated with each drug

L-AMB---liposomal amphotericin; ABLC---amphotericin B lipid complex; d-AMB---desoxycholate amphotericin B

10.1371/journal.pone.0218786.t003

###### Comparative data of patients with mucosal leishmaniasis treated with -AMB and those treated with other options (itraconazole, pentamidine, d-AMB, ABLC, antimonial pentavalent).
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                                                                        Other       L-AMB                  
  ------------------------------------ -------------------------------- ----------- ------- ------ ------- ---------------------------------------
  Sex                                                                                                      
                                       Female                           31          42.5    10     31.3    0.194
                                       Male                             42          57.5    22     68.7     
  Age (years±SD)                       61.8±13.7                        59.1±13.5   0.366                  
  Comorbidities                                                                                            
                                       Systemic arterial hypertension   46          63.0    18     56.3    0.330
                                       Diabetes mellitus                8           11.0    3      9.4     0.555
  Previous cutaneous lesions           37                               82.2        18      78.3   0.464   
  Duration of symptoms                                                                                     
                                       \<1 year                         8           14.5    4      15.4    0.877
                                       1--5 years                       11          20.0    5      19.2     
                                       5--10 years                      19          34.5    11     42.3     
                                       \>10years                        17          31.0    6      23.1     
  Symptoms                                                                                                 
                                       Epistaxis                        51          69.9    23     74.2    0.422
                                       Nasal obstruction                51          69.9    24     77.4    0.296
                                       Rhinorrhea                       39          53.4    15     48.4    0.399
                                       Nasal crust                      30          41.1    16     51.6    0.220
                                       Pruritus                         18          24.7    8      25.8    0.542
                                       Cacosmia                         12          16.4    9      29.0    0.117
                                       Sneeze                           5           5.5     5      16.1    0.087
                                       Odynophagia                      10          13.7    4      12.9    0.593
                                       Hyposmia                         8           11.1    5      16.1    0.342
                                       Facial pain                      10          13.7    3      9.7     0.417
  Local of the mucosal leishmaniasis                                                                       
                                       Nasal                            54          69.0    25     68.8    0.576
                                       Palate                           16          21.9    6      18.8    0.466
                                       Pharynx                          20          27.4    10     31.3    0.428
                                       Larynx                           9           12.3    3      9.4     0.472
  Nasofibroscopy                                                                                           
                                       Septal perfuration               49          63.9    22     72.7    0.248
                                       Granulomatous activity           35          49.3    17     53.1    0.442
                                       Crusts                           48          67.6    17     53.1    0.118
                                       Edema                            10          14.1    7      21.9    0.239
                                       Stenosis                         10          14.1    11     34.4    0.020
                                       Bleeding                         0           0.0     4      12.5    [\*](#t003fn002){ref-type="table-fn"}
                                       Mucosal atrophy                  7           10.0    2      6.3     0.420
                                       Hyperemia                        15          21.4    6      18.8    0.489
                                       Ulceration                       5           7.0     2      6.3     0.624
                                       Purulent drainage                1           1.4     2      6.3     0.227
  CT scan findings (n = 48)                                                                                
                                       Thickening of mucosa             22          71.0    12     70.6    0.614
                                       Sinusopathy                      8           25.8    5      29.4    0.522
                                       Mastoideopathy                   3           9.7     2      11.8    0.588

L-AMB---liposomal amphotericin B

\* cell with value = 0

The AEs associated with the treatment of this condition were analyzed. Approximately 66% of the patients presented with AEs during ML treatment. The most frequent symptoms were infusion-related AEs (fever, chills, sweating, and palpitations) in 48.1% of the participants, followed by phlebitis (20.2%) and nausea/vomiting (18.3%). The most common systemic AEs were electrolyte imbalance (28.8%) and AKI (19.2%) ([Table 4](#pone.0218786.t004){ref-type="table"}). d-AMB had worse AEs than other regimens (P = 0.001; OR = 0.09; 95% CI = 0.09--0.43). ABLC was associated with infusion-related AEs (P\<0.05). Meanwhile, antimonial pentavalent was associated with metabolic disturbances, such as hyperamylasemia and increased liver enzymes. However, fewer electrolyte disorders were observed when amphotericin is used (P\<0.05). Although L-AMB was less nephrotoxic than d-AMB, it was associated with AKI compared with other drugs (P\<0.05).

10.1371/journal.pone.0218786.t004

###### Adverse effects of drugs used in the treatment of mucosal leishmaniasis.
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  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                              \                         Global   Antimonial Pentavalent   Pentamidine   ABLC   d-AMB   Itraconazole   L-AMB                                                   
  --------------------------- ------------------------- -------- ------------------------ ------------- ------ ------- -------------- ------- ------ --- ------ --- ----- ---- ------ ------- -------
  Total Adverse events (AE)   79                        76.0                                                                                                                                  

  Clinical                                                                                                                                                                                    

                              Infusion related AE       50       48.1                     11            44.0   5       45.5           10      76.9   7   50.0   0   0.0   17   54.8   0.026    

                              Phlebitis                 21       20.2                     2             8.0    4       36.4           6       46.2   3   21.4   0   0.0   6    19.4   0.023    

                              Nausea/vomits             19       18.3                     3             12.0   3       27.3           5       38.5   4   28.6   0   0.0   4    12.9            

                              Fever                     9        8.7                      2             8.0    0       0.0            3       23.1   1   7.1    0   0.0   3    9.7             

                              Headache                  9        8.6                      2             8.0    1       9.1            1       7.7    3   21.4   0   0.0   2    6.5             

                              Chest pain                8        7.7                      1             4.0    0       0.0            3       23.1   0   0.0    0   0.0   4    12.9            

                              Tremor                    7        6.7                      0             0.0    0       0.0            4       30.8   0   0.0    0   0.0   3    9.7    0.004   0.031

                              Chills                    6        5.8                      0             0.0    0       0.0            2       15.4   3   21.4   0   0.0   1    3.2             

                              Muscle pain               6        5.7                      3             12.0   0       0.0            1       7.7    0   0.0    0   0.0   2    6.5             

                              Lmbar pain                5        4.8                      0             0.0    0       0.0            1       7.7    0   0.0    0   0.0   4    12.9   0.027    

                              Palpitations              5        4.8                      1             4.0    0       0.0            1       7.7    0   0.0    0   0.0   3    9.7             

                              Arthralgia                4        3.8                      4             16.0   0       0.0            0       0.0    0   0.0    0   0.0   0    0.0    0.003    

                              Sweat                     3        2.9                      0             0.0    0       0.0            2       15.4   0   0.0    0   0.0   1    3.2    0.041    

                              Gastrintestinal other     3        2.9                      3             12.0   0       0.0            0       0.0    0   0.0    0   0.0   0    0.0             

                              Malaise                   2        1.9                      1             4.0    1       9.1            0       0.0    0   0.0    0   0.0   0    0.0             

                              Rash                      1        1.9                      1             4.0    0       0.0            0       0.0    0   0.0    0   0.0   0    0.0             

  Laboratorial                                                                            0.0                                                                                                 

                              Electrolyte disturbance   30       28.8                     1             4.0    4       36.4           6       46.2   7   50.0   0   0.0   12   38.7   0.001   0.001

                              Acute kidney injury       20       19.2                     0             0.0    0       0.0            1       7.7    8   57.1   0   0.0   11   35.5   0.001   0.008

                              Liver enzyme alteration   7        6.7                      3             12.0   0       0.0            0       0.0    0   0.0    0   0.0   0    0.0    0.042    

                              Hyperamylasemia           7        6.7                      7             28.0   0       0.0            0       0.0    0   0.0    0   0.0   0    0.0    0.001    

                              ECG alterations           5        4.8                      5             20.0   0       0.0            0       0.0    0   0.0    0   0.0   0    0.0    0.001    

                              Any mielotoxicity         3        2.9                      1             4.0    1       9.1            1       7.7    0   0.0    0   0.0   0    0.0             

                              Hypoglicemia              1        1.0                      0             0.0    1       9.1            0       0.0    0   0.0    0   0.0   0    0.0             
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\* P value for gray box in the line. The first p value is reference to the first gray box from left to right. The second P value is reference to the second gray box from left to right.

Discussion {#sec008}
==========

Data on L-AMB have been published in the literature since 1990, and in 1997, the FDA approved its use for visceral leishmaniasis. With regard to the efficacy of the drug in the treatment of cutaneous leishmaniasis, the efficacy rate ranged from 84% to 85% \[[@pone.0218786.ref013]--[@pone.0218786.ref015]\]. The few published studies on the treatment of ML with L-AMB presented a small number of patients and reported a high efficacy rate between 83.3% and 100% \[[@pone.0218786.ref006], [@pone.0218786.ref007], [@pone.0218786.ref011]\]. This study enrolled 32 patients treated with L-AMB and was the first to compare L-AMB with other drugs used in the treatment of ML. The cure rate of the group that used L-AMB was 5 times higher than that of the other groups (OR = 4.89, 95%CI \[1.78--13.17\], p = 0.001). The group "healing" was different from "non-healing" considering only the thickness of mucosa on CT, a finding that probably cannot influence therapeutic outcome according with different drugs. The group of patients treated with L-AMB was similar with the group of patients treated with other drugs. The number of patients treated with each drug was too small to compare with those treated with L-AMB, so, we grouped the patients treated with itraconazole, pentamidine, d-AMB, antimonial pentavalent and ABLC. L-AMB is the first choice treatment for visceral leishmaniasis \[[@pone.0218786.ref004]\], and the current study suggest that L-AMB should be considered in the group of first line options.

Our study revealed a therapeutic success rate of 58.3% with antimonial use. Some studies have shown a clinical cure rate between 71.0% and 77.0% of the cases \[[@pone.0218786.ref016], [@pone.0218786.ref017]\]. Recurrence with the use of antimonials is around 22% \[[@pone.0218786.ref002]\]; our study showed a rate of 15.3%. Pentamidine has an efficacy rate of approximately 90%, and recurrence was observed in 25% of the treated cases \[[@pone.0218786.ref003]\]. Moreover, pentamidine (72.7%, 8/11 patients) had a greater efficacy than pentavalent antimonial (58.3%, 14/24 patients). However, no statistically significant difference was observed. In this study, pentamidine had fewer adverse events than other drugs. The use of amphotericin B deoxycholate should be limited, although it produces a small number of recurrences and has better action on mucosal lesions compared to antimonials \[[@pone.0218786.ref018]\]. The number of adverse events was high, and in this study, the actual recurrence rate with the use of amphotericin B deoxycholate cannot be evaluated due to the large number of patients who were not able to complete the treatment.

Studies that compared lipid formulations and the use of ABCL in the treatment of ML are not available. Previous studies on the use of amphotericin B colloidal dispersion in the treatment of ML showed an efficacy rate between 88% and 100% \[[@pone.0218786.ref014]\]. This is the first study that used ABCL in the treatment of ML, and results showed a success rate limited to 46.2% (6/13) and a relapse rate of 7.7% in patients who were treated with a high rate of permanent interruption (61.5%).

Despite the fact that itraconazole is a safe therapeutic option for the treatment of ML, its use had a low efficacy (44.4%). A recent review of the use of azoles in the treatment of ML revealed a 50% efficacy rate: 37% for ketoconazole and 61% for fluconazole and itraconazole, which varied according to the species of *Leishmania*, with the worst responses to *L*. *braziliensis*, which is the most important species in Brazil \[[@pone.0218786.ref019]\]. In total, 38 patients with ML were treated with azoles, showing an efficacy rate of 52.6%, ranging from 23% to 73.3% \[[@pone.0218786.ref020], [@pone.0218786.ref021]\].

In Brazil, ML is considered a public health problem due to its morbidity. Most ML cases involved men due to increased work-related exposure to sandflies \[[@pone.0218786.ref022]\]. In addition, a high level of testosterone increases the production of IL-4 and TGF-β, leading to more severe lesions \[[@pone.0218786.ref023]\]. The most frequent symptoms of ML were nasal obstruction (72.9%), epistaxis (70.0%), and rhinorrhea (52.9%), as observed in the literature \[[@pone.0218786.ref024]\]. According to Marsden (1986), these are among the earliest symptoms of ML. However, late diagnosis was an important factor in our study because only 7 out of 50 patients (14%) were diagnosed within the first year of symptom onset and 32 (64%) after 5 years or longer. In the examination of the mucosa, erythema, infiltration, erosion, ulceration, crusts, and mucopurulent exudate can be observed. The most common findings on rhinoscopy and/or nasofibroscopy were septal perforation, crusts, and granulomatous process in 66.2%, 65.2%, and 58.0% of the cases, respectively. Different results were recorded in the literature, and septal perforation was observed in 41.4--77.0% of the patients \[[@pone.0218786.ref011], [@pone.0218786.ref025]\].

The sinus CT of the face revealed alterations in 86.2% of the patients. Mucosal thickening of some paranasal sinuses occurred in 62.1% (18/29) of the cases, and sinusopathy was observed in 27.2% of the participants. Camargo et al. have revealed the expressive value of 96.0% for paranasal sinus mucosal thickening on CT scan, suggesting that inflammation in patients with ML is not restricted to the nasal mucosa and may extend to the paranasal sinuses and other structures of the respiratory tract \[[@pone.0218786.ref010]\].

In our study, more than 70% of the patients presented with some AEs. The drugs with more AEs were d-AMB and ABCL. Pentavalent antimonial had presented electrocardiographic and pancreatic enzyme changes occurred in 20% and 28% of the patients who used the drug, respectively (p = 0.005; p \<0.001). In addition, these AEs were the primarily cause for the permanent interruption in the use of this drug (8 out of 11 interruptions). The most frequent pentamidine AE was phlebitis (36.4%), followed by nausea and vomiting (27.3%). Despite the high frequency rate of the general AEs in this study, the use of pentamidine is considered safe, as previously described \[[@pone.0218786.ref011]\]. The use of ABCL led to a significantly high incidence rate of phlebitis (46.2%) and tremors (30.8%) compared to other leishmanicidal drugs (p = 0.029 and p = 0.005). The AEs of ABLC are more common than those of L-AMB \[[@pone.0218786.ref026]\]. These observations have important clinical relevance because the infusion in 8 of the 13 patients who used ABLC was interrupted. Nevertheless, the liposome of amphotericin B attenuates the release of cytokines, which decreases infusion-related AEs \[[@pone.0218786.ref027]\]. In contrast, the rapid removal of ABCL from the circulation by reticuloendothelial tissues, particularly in the liver \[[@pone.0218786.ref028]\], may result in the release of proinflammatory cytokines from the surrounding macrophages and contribute to the AEs associated with the administration of ABCL.

The major limitations of this study are the retrospective analysis, few patients for sub-analysis, different duration of the disease. Unfortunately these biases cannot be controlled. The doses of drugs were different among patients with the same therapeutic group, considering that this was not a clinical trial.

This retrospective study suggests that L-AMB is an effective drug in the treatment of ML. Approach of patients with ML should be reconsidered and L-AMB could be considered as a first line of therapy. A controlled study is need in this context, but at this moment, this is the best evidence we have to treat ML. The treatment of ML treatment is still far from ideal because the best-acting drugs for this condition have numerous AEs, and drugs that are safer to use have a low efficacy. L-AMB presented with better results than other drugs used for the treatment of ML. However, the incidence rate of nephrotoxicity associated with this drug is high.
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